XFOR
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- X4 Pharmaceuticals received European Commission approval for XOLREMDI, the first approved treatment for WHIM syndrome in the EUApr 29, 2026
- X4 Pharmaceuticals announces restructuring of business operations designed to drive long-term value creationSep 17, 2025
- X4 Pharmaceuticals closes upsized $85 million private placementAug 13, 2025
- X4 shares promising Phase 2 chronic neutropenia data at EHA 2025Jun 16, 2025